RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to outsmart Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a pill that makes chemotherapy more effective)—is safe and can shrink tumors in people with B-cell lymphoma that has returned or stopped r…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
Double attack: vaccine boosts CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining a patient's own modified immune cells (CAR T-cells) with a special vaccine is safe and possible for people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T-cells are designed to find and kil…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
Engineered immune cells aim to stop lymphoma return after transplant
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or returning lymphoma will receive the treatment. The…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New immune cell combo takes on tough lymphoma
Disease control Recruiting nowThis study tests whether a new treatment combining specially designed immune cells (ONC-PluReceptor NK cells) with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has returned or not responded to prior therapies. About 30 adults aged …
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: RECURRENT B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC